Vincenza Conteduca is an expert in Oncology at Ospedali Riuniti di Foggia (Italy). As of November 2026, ScienceLeadR ranks Vincenza Conteduca in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Genital Diseases, Male. Vincenza Conteduca has authored 265 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 7 of them ongoing. SLR score: 1,211 (community average: 125). How the SLR is computed.

LeadR Profile

Vincenza Conteduca Ospedali Riuniti di Foggia Italy
1 211 ScienceLeadR Reputation 1211
Network Map

Oncology

Subspecialties: Urology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2011 - 2026
Source: PubMed

University of Foggia - Associate Professor

2021 - 2026

Ospedali Riuniti di Foggia

2025 - 2026

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 265

Citations

Citations: 6 268 1st author: 79 Last author: 4 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Prognostic impact of variants of uncertain significance (VUS) in BRCA genes and homologous recombination repair (HRR) genes in prostate cancer: a real-world multicenter study.
PMID 42972372 — genes, recombination, genetic, homologous recombination, neoplasms, prostate, recombinational dna repair, prostatic neoplasms, therapeutics
BMC Med20260
Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.
PMID 42376796 — neoplasms, prostate, biomarkers, immunotherapy, prostatic neoplasms, precision medicine, therapeutics
Expert Rev Anticancer Ther20262
Serum [-2]proPSA as a Candidate Phenotypic Correlate of Molecular Alterations and Prognostic Marker in Metastatic Castration-Resistant Prostate Cancer.
PMID 42959566 — serum, neoplasms, prostate, prostatic neoplasms, castration, therapeutics
Prostate Cancer20260
Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations.
PMID 42609124 — genes, recombination, genetic, homologous recombination, neoplasms, prostate, recombinational dna repair, prostatic neoplasms, castration, therapeutics, genes, brca2
Int J Cancer20261
BRCA Testing in Prostate Cancer: A Histopathologist's Perspective.
PMID 42587595 — research design, poly(adp-ribose) polymerases, neoplasms, prostate, poly adenosine diphosphate ribose, molecular diagnostic techniques, recombinational dna repair, carcinoma, intraductal, noninfiltrating, nucleic acids, prostatic neoplasms, tissues
Diagnostics (Basel)20260

Clinical Studies 13

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 6
Phase 3 5
N/A 2

By status:

Recruiting 6
Unknown 3
Active not recruiting 2
Completed 2

By type:

Interventional 11
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 1
multicentricup10 11

Main Topics

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator s Choice in Chemotherapy na ve Metastatic Castration resistant Prostate Cancer
2025-520555-89-00 — neoplasms, prostate, drug therapy, prostatic neoplasms, castration, therapeutics, chemotherapy
Phase 3Recruiting2025
Pasritamig vs Placebo in late line Metastatic Castration resistant Prostate Cancer (mCRPC)
2025-520927-26-00 — cells, kallikreins, neoplasms, prostate, prostatic neoplasms, castration, t-lymphocytes
Phase 3Recruiting2025
A Phase 3 Study Comparing BMS 986365 versus Investigator s Choice of Therapy in Participants with Metastatic Castration resistant Prostate Cancer
2024-517422-25-00 — docetaxel, androgens, receptors, androgen, neoplasms, prostate, prostatic neoplasms, castration, therapeutics
Phase 3Active not recruiting2025
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide REINFORCE Trial
NCT07333066 — docetaxel, neoplasms, prostate, tablets, hormones, prostatic neoplasms, therapeutics
Phase 3Recruiting2026
APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer a rANdomized trial PERSIAN
2022-501894-37-00 — radiotherapy, androgens, neoplasms, prostate, hormones, prostatic neoplasms, therapeutics
Phase 2Recruiting2023

LeadR Networks

Main global connection map